Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Rachel Natrajan"'
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Supplier and catalogue number of compounds included in high-throughput drug screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::373d13022c92315ae677f6d84de762c1
https://doi.org/10.1158/1535-7163.22507552.v1
https://doi.org/10.1158/1535-7163.22507552.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Additional compounds included in the isogenic high-throughput drug screen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5821d655b15b0e0045324aa26cbbbacc
https://doi.org/10.1158/1535-7163.22507534.v1
https://doi.org/10.1158/1535-7163.22507534.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Results from the dasatinib target siRNA screen, see also Figure S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aee401169a982d676f1c213525027335
https://doi.org/10.1158/1535-7163.22507543.v1
https://doi.org/10.1158/1535-7163.22507543.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Supplementary Figure 1 ARID1A mutations in the panel of OCCC tumour cell line models with corresponding protein expression. Supplementary Figure 2 Un-cropped western blots from main and supplementary figures. Supplementary Figure 3 ARID1A selective e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4d5e637be03d18a6d8e584452ea31a
https://doi.org/10.1158/1535-7163.22507555.v1
https://doi.org/10.1158/1535-7163.22507555.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
siRNA library gene list for dasatinib resistance screen, see also figure 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::965c604b86d9c18e6e6f0ff928f453bd
https://doi.org/10.1158/1535-7163.22507531
https://doi.org/10.1158/1535-7163.22507531
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Results from the siRNA kinase and tumour suppressor dasatinib resistance screen, see also Figure 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9239f1f21cf9623a66f6802ccc21372
https://doi.org/10.1158/1535-7163.22507540.v1
https://doi.org/10.1158/1535-7163.22507540.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
ARID1A mutation status in OCCC panel determined by whole exome sequencing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b24fba3050c182abfaf1b8866ca7694
https://doi.org/10.1158/1535-7163.22507528
https://doi.org/10.1158/1535-7163.22507528
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Results from the high throughput drug screen in the non-isogenic OCCC cell line panel, see also Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38bd9baa925aa33da8cf2a2096ebdb64
https://doi.org/10.1158/1535-7163.22507522
https://doi.org/10.1158/1535-7163.22507522
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
Compounds used in the high throughput drug screen in the panel of OCCC cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f9a8677c5cf8f21b816a09c5dc54559
https://doi.org/10.1158/1535-7163.22507537.v1
https://doi.org/10.1158/1535-7163.22507537.v1
Autor:
Alan Ashworth, Christopher J. Lord, Sourav Bandyopadhyay, Kevan M. Shokat, Rebecca S. Levin, James T. Webber, John D. Gordan, Chris Torrance, Jonathan D. Moore, Claire Mahoney, Holly Astley, Josephine Joel, Rachel Natrajan, Helen Pemberton, Rumana Rafiq, Asha Kigozi, James Campbell, Simon McDade, Chris T. Williamson, Ilirjana Bajrami, Rachel Brough, Rowan E. Miller
New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based drug screens in OCCC tumor ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64787c15cc476e3abe0f82e5ec7834ee
https://doi.org/10.1158/1535-7163.c.6538717.v1
https://doi.org/10.1158/1535-7163.c.6538717.v1